Healthcare Industry News: benign prostatic hyperplasia
News Release - July 16, 2010
Sun Pharma Announces USFDA Approval for Generic Flomax(R)MUMBAI, India--(HSMN NewsFeed)--Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE:524715) announced that USFDA has granted approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Flomax ®, tamsulosin capsules.
These tamsulosin hydrochloride capsules, 0.4 mg are therapeutically equivalent to Flomax® Capsules 0.4 mg from Boehringer Ingelheim Pharmaceuticals, Inc.
Tamsulosin hydrochloride capsules are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).
Flomax® is a registered trademark of Astellas Pharma Inc.
About Sun Pharmaceutical Industries Ltd.
Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, orthopedics and ophthalmology. The company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.
Source: Sun Pharmaceutical Industries
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.